Dose Sildenafil Citrate Reduce the Incidence of Emergency Cesarean Section and Fetal Distress During Labor? A Randomized Double-Blinded Clinical Trial

Sharami, Seyedeh Hajar; Milani, Forozan; Kabodmehri, Roya; Naghdipour, Misa; Mahmoudi Isaabadi, Azade; Haghparast Ghadim-Limudahi, Zahra

doi:10.18502/jri.v25i1.15198

Dose Sildenafil Citrate Reduce the Incidence of Emergency Cesarean Section and Fetal Distress During Labor? A Randomized Double-Blinded Clinical Trial

Authors

Seyedeh Hajar Sharami

Forozan Milani

Roya Kabodmehri

Misa Naghdipour

Azade Mahmoudi Isaabadi

Zahra Haghparast Ghadim-Limudahi

Reproductive Health Research Center, Department of Obstetrics and Gynecology, School of Medicine, Al-Zahra Hospital, Guilan University of Medical Sciences, Rasht, Iran

10.18502/jri.v25i1.15198

Abstract

Background: Fetal distress (FD) is one of the most frequent causes of emergency cesarean section (CS) due to the insufficient uteroplacental blood supply during labor. There is a theory that Sildenafil citrate (SC) may improve the uteroplacental blood supply and decrease fetal hypoxia and FD. In this study, the effect of SC on the incidence of FD and emergency C/S was analyzed. Methods: In a randomized double-blinded clinical trial, a total of 208 low-risk subjects who met our stringent inclusion criteria were randomly assigned into two groups: the Sildenafil citrate group (n=104) and the placebo group (n=104). These participants were referred to our referral gynecology and obstetrics department for delivery between July 2022 to September 2022. The SC group received oral SC at a dose of 50 mg every 6 hr, up to a maximum of three times. The final maternal-fetal-neonatal results were recorded and all data were analyzed using SPSS version 23. Results: The mean age of mothers was 28.98±5.6 years and 120 cases were primigravid (57.7%). Out of a total of 208 pregnant subjects, 168 subjects delivered through normal vaginal delivery (80.8%) and 40 cases underwent emergency CS (19.2%). The number of NVD in Sildenafil group was significantly more than placebo group (87.5% versus 74%) and SC decreased the rate of emergency CS to 87.5% (RR=2.46%, 95%CI 1.19-5.08). Also, SC decreased the rate of FD to 53.8% (RR=2.83%, 95%CI of 1-8.24). The hemoglobin level was significantly higher in SC group 6 hr after delivery (11.06±1.26 versus 10.75±1.14, respectively; p=0.049). Also, higher Apgar scores at both the 1st and 5th min after delivery were observed in SC group (p=0.001). Conclusion: The results showed that SC can effectively decrease the rate of emergency CS and FD during labor.

Keywords

Cesarean section

Fetal distress

Labor

Sildenafil citrate

Kale I. Does continuous cardiotocography during labor cause excessive fetal distress diagnosis and unnecessary cesarean sections? J Matern Fetal Neonatal Med. 2022;35(6):1017-22.

Lakhno IV, Uzel K. Diagnosing antenatal fetal distress. Ginekol Pol. 2021.

Maybin JA. Hypoxia and reproductive health. Reproduction. 2021;161(1):E1-2.

Turner JM, Mitchell MD, Kumar SS. The physiology of intrapartum fetal compromise at term. Am J Obstet Gynecol. 2020;222(1):17-26.

Evans MI, Britt DW, Eden RD, Evans SM, Schifrin BS. Earlier and improved screening for impending fetal compromise. J Matern Fetal Neonatal Med. 2022;35(15):2895-903.

Dunn L, Flenady V, Kumar S. Reducing the risk of fetal distress with sildenafil study (RIDSTRESS): a double-blind randomised control trial. J Transl Med. 2016;14:15.

Umar BU, Haque M. Growing concern over rising caesarean section rates: Is it a problem for low-and middle-income countries only? Adv Hum Biol. 2022;12(2):93.

Betran AP, Ye J, Moller AB, Souza JP, Zhang J. Trends and projections of caesarean section rates: global and regional estimates. BMJ Glob Health. 2021;6(6):e005671.

Eyi EGY, Mollamahmutoglu L. An analysis of the high cesarean section rates in Turkey by Robson classification. J Matern Fetal Neonatal Med. 2021;34(16):2682-92.

Buhimschi CS, Garfield RE, Weiner CP, Buhimschi IA. The presence and function of phosphodiesterase type 5 in the rat myometrium. Am J Obstet Gynecol. 2004;190(1):268-74.

Hafeez MA, Kortam AM, Youssef AM, Reda A, Abdelrahman RM. Effect of nitric oxide donors on uterine and sub-endometrial blood flow in patients with unexplained infertility: a randomized controlled trial. Int J Reprod Contraception Obstet Gynecol. 2021;10(6):2178-85.

Bahaa HA. Efficacy of sildenafil citrate in women with unexplained recurrent miscarriage preconceptional and during 1st trimester of pregnancy. Evid Based Women's Health J. 2018;8(1):138-44.

Russo FM, Benachi A, Van Mieghem T, De Hoon J, Van Calsteren K, Annaert P, et al. Antenatal sildenafil administration to prevent pulmonary hypertension in congenital diaphragmatic hernia (Stop-PH): study protocol for a phase I/IIb placenta transfer and safety study. Trials. 2018;19(1):524.

Ghaleb MM, Labib YS, Wahba KA. Sildenafil plus low dose aspirin for prevention of preeclampsia: a randomized controlled trial. Open J Obstet Gynecol. 2021;11(02):189.

Mohammadi E, Teymoordash SN, Norouzi AR, Norouzi F, Norouzi HR. Comparison of the effect of nifedipine alone and the combination of nifedipine and sildenafil in delaying preterm labor: a randomized clinical trial. J Family Report Health. 2021;15(2):112-7.

Maher MA, Sayyed TM, El-Khadry SW. Nifedipine alone or combined with sildenafil citrate for management of threatened preterm labor: a randomized trial. BJOG. 2018;126(6):729-35.

Maged M, Wageh A, Shams M, Elmetwally A. Use of sildenafil citrate in cases of intrauterine growth restriction (IUGR); a prospective trial. Taiwan J Obstet Gynecol. 2018;57(4):483-6.

Hessami K, Cozzolino M, Shamshirsaz AA. The effect of phosphodiesterase-5 inhibitors on uteroplacental and fetal cerebral perfusion in pregnancies with fetal growth restriction: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2021;267:129-36.

Nath J, Chaube S, Rani N, Verma P. A study on sildenafil citrate in the treatment of IUGR & Oligohydramnios. Invest Gynecol Res Women’s Health. 2021;4(2):431-5.

Russo FM, De Bie F, Hodges R, Flake A, Deprest J. Sildenafil for antenatal treatment of congenital diaphragmatic hernia: from bench to bedside. Curr Pharm Des. 2019;25(5):601-8.

Turner J, Kumar S. Neurodevelopmental outcomes in infants following intrapartum maternal oral sildenafil citrate treatment. Am J Obstet Gynecol. 2021;224(3):316-7.

Turner J, Dunn L, Tarnow-Mordi W, Flatley C, Flenady V, Kumar S. Safety and efficacy of sildenafil citrate to reduce operative birth for intrapartum fetal compromise at term: a phase 2 randomized controlled trial. Am J Obstet Gynecol. 2020;222(5):401-14.

Turner JM, Russo F, Deprest J, Mol BW, Kumar S. Phosphodiesterase-5 inhibitors in pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes. BJOG. 2022;129(11):1817-31.

Ahmed WS, Geethakumari AM, Biswas KH. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors. Biomed Pharmacother. 2021;134:111128.

G Shilkrut A, C Hsu R, M Fuks A. Fetal heart rate tracing category II: a broad category in need of stratification. Neoreviews. 2021;22(2):e88-94.

Krause BJ. Novel insights for the role of nitric oxide in placental vascular function during and beyond pregnancy. J Cell Physiol. 2021;236(12):7984-99.

Wareing M, Myers JE, O’Hara M, Baker PN. Sildenafil citrate (Viagra) enhances vasodilatation in fetal growth restriction. J Clin Endocrinol Metab. 2005;90(5):2550-5.

Dastjerdi MV, Hosseini S, Bayani L. Sildenafil citrate and uteroplacental perfusion in fetal growth restriction. J Res Med Sci. 2012;17(7):632-6.

Dunn L, Greer R, Flenady V, Kumar S. Sildenafil in pregnancy: a systematic review of maternal tolerance and obstetric and perinatal outcomes. Fetal Diagn Ther. 2017;41(2):81-8.